Monopar Therapeutics Inc.

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for cancer and rare diseases. Its current work centers on novel radiopharmaceuticals for oncology, antibody-based programs, and other proprietary therapies designed to address serious conditions with limited treatment options. The company’s pipeline includes candidates aimed at advanced cancers, such as soft tissue sarcoma and other hard-to-treat oncology settings, as well as a treatment program for Wilson disease, a rare genetic disorder. Monopar Therapeutics Inc. operates as a research-driven drug developer, advancing its assets through preclinical and clinical development rather than commercial product sales. Based in Wilmette, Illinois and founded in 2014, Monopar Therapeutics Inc. plays a specialized role in the healthcare market by pursuing innovative therapies for patients with significant unmet medical needs.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc.

Employees

22

Headquarters

Wilmette, IL, United States

Website

www.monopartx.com